Skip to main content

Table 2 Difference in clinicopathological features due to body mass index categorized

From: Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy

  Body mass index categorized p value Body mass index categorized p value
Underweight
(n = 49)
Nomal / Overweight
(n = 310)
Nomal / Overweight(n = 310) Obese(n = 19)
Age (years old) 0.928
  ≤ 60 33 (67.3%) 209 (67.4%)   209 (67.4%) 13 (68.4%)
  > 60 16 (32.7%) 101 (32.6%) 0.992 101 (32.6%) 6 (31.6%)
Tumor size (mm) 0.267
  ≤ 20.0 9 (18.4%) 51 (16.5%)   51 (16.5%) 5 (26.3%)
  > 20.0 40 (81.6%) 259 (83.5%) 0.738 259 (83.5%) 14 (73.7%)
Skin infiltration 0.004
 Negative 36 (73.5%) 270 (87.1%)   270 (87.1%) 12 (63.2%)
 Positive 13 (26.5%) 40 (12.9%) 0.012 40 (12.9%) 7 (36.8%)
Lymph node status 0.751
 Negative 17 (34.7%) 109 (35.2%)   109 (35.2%) 6 (31.6%)
 Positive 32 (65.3%) 201 (64.8%) 0.949 201 (64.8%) 13 (68.4%)
Estrogen receptor 0.117
 Negative 28 (57.1%) 187 (60.3%)   187 (60.3%) 8 (42.1%)
 Positive 21 (42.9%) 123 (39.7%) 0.673 123 (39.7%) 11 (57.9%)
Progesterone receptor 0.043
 Negative 35 (71.4%) 254 (81.9%)   254 (81.9%) 12 (63.2%)
 Positive 14 (28.6%) 56 (18.1%) 0.085 56 (18.1%) 7 (36.8%)
HER2 0.982
 Negative 31 (63.3%) 195 (62.9%)   195 (62.9%) 12 (63.2%)
 Positive 18 (36.7%) 115 (37.1%) 0.961 115 (37.1%) 7 (36.8%)
Ki67 0.409
  ≤ 14% 11 (22.4%) 102 (32.9%)   102 (32.9%) 8 (42.1%)
  > 14% 38 (77.6%) 208 (67.1%) 0.143 208 (67.1%) 11 (57.9%)
Intrinsic subtype HRBC 0.054
 non-HRBC 28 (57.1%) 184 (59.4%)   184 (59.4%) 7 (36.8%)
 HRBC 21 (42.9%) 126 (40.6%) 0.770 126 (40.6%) 12 (63.2%)
Intrinsic subtype HER2BC 0.688
 non- HER2BC 38 (77.6%) 232 (74.8%)   232 (74.8%) 15 (78.9%)
 HER2BC 11 (22.4%) 78 (25.2%) 0.683 78 (25.2%) 4 (21.1%)
Intrinsic subtype TNBC 0.098
 non- TNBC 32 (65.3%) 204 (65.8%)   204 (65.8%) 16 (84.2%)
 TNBC 17 (34.7%) 106 (34.2%) 0.945 106 (34.2%) 3 (15.8%)
Objective response rate 0.476
 Non-Responders 8 (16.3%) 32 (10.3%)   32 (10.3%) 1 (5.3%)
 Responders 41 (83.7%) 278 (89.7%) 0.215 278 (89.7%) 18 (94.7%)
Pathological response 0.103
 Non-pCR 29 (59.2%) 205 (66.1%)   205 (66.1%) 16 (84.2%)
 pCR 20 (40.8%) 105 (33.9%) 0.343 105 (33.9%) 3 (15.8%)
TILs 0.073
 Low 32 (65.3%) 163 (52.6%)   163 (52.6%) 14 (73.7%)
 High 17 (34.7%) 147 (47.4%) 0.097 147 (47.4%) 5 (26.3%)
  1. HER: human epidermal growth factor receptor. HRBC: hormone receptor-positive breast cancer (ER+ and/or PgR+). HER2BC: human epidermal growth factor receptor 2-enriched breast cancer (ER-, PgR-, and HER2+). TNBC: triple negative breast cancer (ER-, PgR-, and HER2-). pCR: pathological complete response. TILs: tumor-infiltrating lymphocytes